Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Antibody Neutralizes Key Anthrax Toxins

By Biotechdaily staff writers
Posted on 23 May 2003
In rat studies, data have shown that one molecule of a fully human antibody against the key toxin of anthrax is capable of neutralizing more than two anthrax toxin molecules.

The antibody, AVP-8C1, binds to and neutralizes the protective antigen, PA. More...
PA is a component of anthrax toxins that plays an important role in providing a portal for lethal factor (LF) and edema factor (EF) to enter the intracellular compartment and have a lethal effect. The research results showed that a single dose of AVP-8C1 completely protected rats subsequently exposed to a lethal dose of recombinant anthrax toxins.

The antibody is being developed by Avanir Pharmaceuticals (San Diego, CA, USA; www.avanir.com) for use as a prophylactic and therapeutic drug to prevent and treat anthrax infections. In contrast to the currently available anthrax vaccine, AVP-8C1 offers immediate protection after a single dose. Compared to antibiotics, AVP-8C1 acts against the key gateway component (PA) of the anthrax, denying entry to the LF and EF toxins.

"The potency this antibody exhibits is extremely high,” said Dr. Philip Morrow, the co-inventor of the Xenerex technology used by Avanir to develop the antibody. "Although speculative, AVP-8C1 may also play a role in the prevention and treatment of infections by antibiotic-resistant strains of anthrax.”




Related Links:
Avanir >>

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Automatic CLIA Analyzer
Shine i6000
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.